 This study is a randomized, open-label, multiple dosing, 3-way crossover design to evaluate the drug-drug interaction between Atorvastatin Lipitor and Fenofibric Trilipix acid in healthy male subjects. Subjects will receive repeated dose of Atorvastatin 40mg1Tabday or Fenofibric acid 135mg1Capday or Atorvastatin 40mg1TabdayFenofibric acid 135mg1Capday. Each treatment period was separated by a washout period of at least 8 days. 